Jason Foster, CEO of Ori Biotech, discusses the difficulties preventing more widespread adoption of these advanced therapies.

Niktimvo marks the first FDA-approved therapy targeting CSF-1R to address inflammation and fibrosis in chronic ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and ...

A new offering in collaboration with Progyny, Inc makes fertility/family-building services more accessible and equitable.

Pharmaceutical companies’ direct-to-patient (DTP) programs have recently sparked conversations and criticism in fear of their ...

Organizations including Gilead, Eli Lilly, and AbbVie announced a number of deals addressing inflammatory diseases, multiple myeloma, and other disease areas. With the start of the annual JP Morgan ...

Novo Holdings announced an investment in a $200M Series A launch financing for Swiss company Windward Bio. 1 The clinical stage drug development company is developing treatments for immunological ...

Blue Shield of California issued a statement regarding the devastating wildfires that have spread across large sections of the state. 1 While the combination of flames and winds continue to cause ...

‘Shape Shifting’ is a creator-led series that focuses on the scientific and cultural impact of GLP-1s. The two biggest stories in pharma in recent years have been the rise in popularity of GLP-1s and ...

Johnson & Johnson (J&J) announced that it has acquired Intra-Cellular Therapies, a biopharmaceutical company. According to the company, the acquisition includes Caplyta (lumateperone), a once-daily ...

Under terms of the deal, GSK will also acquire IDRX-42, a tyrosine kinase inhibitor designed to treat both primary and secondary KIT mutations in patients with gastrointestinal stromal tumors. GSK ...

Amylyx Pharmaceuticals named Dan Monahan as its chief commercial officer. 1 According to a press release, he is assuming the role in time to oversee the commercialization of avexitide, a GLP-1 ...